Zantac and Cancer Risk: What Happened to Ranitidine and the Lawsuits

For decades Zantac sat next to the antacids in millions of medicine cabinets, and then in April 2020 the FDA asked every maker of ranitidine to take it off the market. Since then, most of the headlines have been about lawsuits, and many of them are out of date. This post covers why the drug was pulled, which cancers were alleged, what the courts have actually decided, and whether a claim still makes sense for someone diagnosed today. If you took ranitidine for years and now have a cancer diagnosis, a defective drug lawyer at Boesen Law can look at your history and give you a straight answer.

What Zantac Is and Why NDMA Put It Under a Microscope

Zantac was the best-known brand of ranitidine, an H2 blocker that lowers the amount of acid the stomach produces. It was sold over the counter for heartburn and sour stomach, and in prescription strength for ulcers, GERD, and Zollinger-Ellison syndrome.

The Impurity

The problem was not ranitidine’s job in the body. It was N-nitrosodimethylamine, or NDMA, a chemical the FDA describes as a probable human carcinogen. Small amounts turn up in food and water, and the FDA has said that low dietary exposure is not expected to raise cancer risk. The concern with ranitidine was different: FDA testing found that NDMA levels in ranitidine could climb over time and rise faster when the product was stored above room temperature. A bottle that tested fine at the factory could be a different product after a hot summer in a delivery truck or a year on a shelf.

Why That Matters to a Claim

NDMA was not unique to heartburn pills. A few years earlier, a wave of blood pressure medication recalls involved nitrosamine impurities in valsartan. What made ranitidine different is that the molecule itself appeared to break down into NDMA, so the question in court became whether the drug, not just a bad batch, caused cancer. That distinction ended up deciding most of the litigation, which is why Boesen Law starts every drug review with the product’s chemistry and the patient’s timeline side by side.

For answers to your questions, call:
(303) 999-9999

Zantac Timeline: Warning, Withdrawal, and a Reformulated Return

The regulatory story runs about six years. Here are the dates that matter for anyone trying to match their own use to what regulators knew:

1. Summer 2019. The FDA learns that some ranitidine samples contain NDMA.
2. September 13, 2019. The agency publicly alerts patients and doctors that NDMA has been found in ranitidine.
3. September 24, 2019. Sandoz starts the first voluntary recall of ranitidine capsules. Other manufacturers and retailers follow over the next months.
4. October 2019. The FDA publishes lab methods manufacturers can use to test ranitidine, and holds NDMA to an acceptable daily intake of 96 nanograms.
5. April 1, 2020. The FDA requests removal of all ranitidine products, prescription and over the counter, from the U.S. market. The agency tells consumers to stop taking OTC ranitidine and throw it away.
6. 2021. A product sold under the Zantac 360 name arrives on shelves, but it contains famotidine, a different H2 blocker, not ranitidine.
7. November 2025. The FDA approves reformulated ranitidine tablets after manufacturing changes aimed at NDMA formation during shelf life. The label comes with strict handling rules: keep tablets in the original bottle with the desiccant, open one bottle at a time, and discard unused tablets 90 days after opening.

If your use of ranitidine falls before April 2020, the old product and its storage problems are what matter for your history. Our team can help you build that timeline from pharmacy and medical records.

What Kind of Cancer Does Zantac Cause?

No court or regulator has found that Zantac causes cancer. What exists is a set of cancers that plaintiffs alleged were linked to NDMA exposure from ranitidine. In the federal litigation, plaintiffs narrowed their claims to five “designated” cancers:

• Bladder cancer. Among the most common diagnoses in both the federal and state filings.
• Stomach (gastric) cancer. One of two digestive tract cancers on the list.
• Esophageal cancer. The other digestive tract cancer, often pleaded alongside gastric cancer.
• Liver cancer. One of the five cancers carried into the federal expert rulings.
• Pancreatic cancer. The fifth designated cancer in the federal cases.

Plaintiffs in the federal cases withdrew claims for breast, kidney, colorectal, prostate, and lung cancer before the key rulings. Some state court cases did pursue other cancers, including prostate and colorectal, and juries in several of those trials sided with the manufacturers. Lawsuits like these belong to a wider mass tort practice, where one product and one alleged injury repeat across thousands of families, and Boesen Law tracks each one so we can tell clients where their diagnosis actually stands.

Where Zantac Lawsuits Stand in 2026

This is the part most online summaries get wrong, so it is worth being precise about what courts have ruled.

The Federal MDL

Federal cases were consolidated in Florida as MDL No. 2924. In December 2022 the judge excluded all of the plaintiffs’ general causation experts, finding their methods unreliable, and entered judgment against the claims for the five designated cancers. Plaintiffs appealed to the Eleventh Circuit, which heard oral argument in October 2025. That appeal was still pending in spring 2026, when plaintiffs asked the Delaware court to wait for it and the court declined. Unless the appeals court reverses, the federal claims stay dismissed.

Delaware

Delaware held the largest group of state cases, more than 80,000 of them. In mid-2024 a Delaware trial judge let the plaintiffs’ experts testify, but in July 2025 the Delaware Supreme Court reversed that ruling and held that the causation analysis had to focus on ranitidine itself, not on NDMA in general. On remand, the Superior Court granted summary judgment on April 14, 2026, which the court noted would lead to dismissal of more than 80,000 cases filed before December 1, 2025. In a separate January 2026 opinion, the same court dismissed 277 cases as filed too late, treating April 1, 2020 as the date the public was on notice of the alleged link.

Settlements

Several manufacturers settled rather than try every case. In October 2024, GSK announced agreements to resolve about 80,000 state court cases, roughly 93 percent of those pending against it, for up to $2.2 billion, while denying liability. Pfizer and Sanofi also settled thousands of cases in 2024 on confidential terms, according to news reports.

What This Means for a New Claim

Put simply, the settlement money went mostly to people who had already filed, and the cases that remain face hostile rulings on the science. These fights over scientific evidence in drug lawsuits are not over, but anyone promising a quick Zantac payout in 2026 is not describing the real docket. Boesen Law will tell you if the facts of your case give it a realistic path.

Deadlines for a Ranitidine Claim in Colorado

Colorado sets a two-year deadline for claims against a manufacturer or seller of a product under C.R.S. § 13-80-106, and that includes failure-to-warn claims over a drug. Under C.R.S. § 13-80-108, the clock generally starts when you knew, or reasonably should have known, about both the injury and its cause. Courts in the Zantac litigation have treated the April 2020 withdrawal as the point when the public link became widely known, which means someone diagnosed years ago may already be outside the window. Colorado’s time limits on personal injury cases have exceptions for minors and people under a disability, and a family member’s death starts its own clock.

Deadlines are only half of it. A drug claim still needs the elements of a product liability claim: a defect or inadequate warning, an injury, and proof that the product caused it. If you are unsure whether your dates work, a short call with Boesen Law can settle it before more time passes.

Jon C. Boesen on Drug Cases That Stall in Court

Jon C. Boesen, founder of Boesen Law, who has overseen mass tort and class action claims over defective pharmaceutical drugs for much of his 36-year career, says:

“People call us about Zantac because they saw an ad in 2021 and never heard what happened next. I tell them the truth: the science fight has gone badly for plaintiffs, and a cancer diagnosis plus years of heartburn pills is not enough on its own. What I look for is the whole record, the pharmacy fills, how long and how often, the diagnosis date, and whether another drug or a medical provider played a part. Sometimes the strongest case sitting inside a Zantac story is not about Zantac at all. We would rather give you an honest no than file something that goes nowhere.”

That honesty runs both ways. When the facts do support a claim against a drug company or a medical provider, the firm is prepared to take it through expert discovery and trial.

What Cases Like Yours Have Recovered

Drug and medical cases turn on expert proof, and Boesen Law has carried that kind of case the distance. In one medical malpractice matter, a client was injured during a routine medical procedure and faced high medical bills; after complex litigation and a trial, the firm secured a $1,000,000 settlement to cover those costs. Our case results show how the firm has handled other serious injury claims across Colorado.

If a medication or a treatment decision changed your health, we want to hear the details.

Contact Boesen Law About a Zantac or Drug Injury Question

Drug litigation moves slowly and changes often, and the answer for your situation depends on dates and records most people have never pulled together. Boesen Law is a boutique firm with big results, and we will review your medication history, diagnosis, and deadlines without charging you for the conversation.

Contact Boesen Law to set up a free, in-person consultation, or call any time of day or night. We handle injury cases on contingency, so you owe no attorney fee unless we recover compensation for you.

FAQs About Zantac and Cancer

Is Zantac still a cancer risk?

The ranitidine sold before April 2020 is no longer on the market, and the FDA told consumers to stop taking and discard any they still had. If you find an old bottle, do not take it. The reformulated ranitidine approved in November 2025 was cleared after testing aimed at the NDMA problem, but it depends on the storage rules on its label. Current Zantac 360 products contain famotidine, not ranitidine.

Can taking Zantac every day be harmful?

Daily use is what the NDMA concern centered on. When it pulled ranitidine, the FDA said that sustained higher levels of NDMA exposure may increase the risk of cancer, and many plaintiffs had used the drug every day for years. Courts, however, have not accepted that ordinary daily use caused the cancers alleged. If you took it for a long stretch and have symptoms or a family history that worries you, raise it with your doctor.

Are there any antacids linked to cancer risk?

Ranitidine was the main heartburn drug removed over a cancer-causing impurity. When the FDA pulled it, the agency said its testing found no NDMA in famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid), or omeprazole (Prilosec). In April 2020, one maker of another H2 blocker, nizatidine, also recalled an oral solution over NDMA levels. The FDA keeps a running list of ranitidine updates and recalls on its website.

Can I still file a Zantac lawsuit?

Possibly, but the path is narrow. Federal cases were dismissed and went up on appeal, most Delaware cases were ended by the April 2026 ruling, and Colorado’s two-year product deadline may already have run for older diagnoses. A lawyer who has looked at your pharmacy records and diagnosis date can tell you whether any claim remains, whether it runs against a drug maker or someone else in your care. Boesen Law’s product liability lawyers can review that for you at no cost.

Call (303) 999-9999 or complete a Free Case Evaluation form